Back to All Combinations

ctDNA MRD Positive

Poor Prognosis
20.00% Prevalence Level 2A Emerging Targets
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
ctDNA
Treatment Implications

ctDNA MRD identifies high recurrence risk. DYNAMIC trial validated.

Recommended Treatments
Adjuvant chemotherapy
Intensive surveillance
Treatments to Avoid

No specific contraindications noted

Study References

DYNAMIC trial

Key Statistics
20.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Transforming adjuvant decisions.
Information

Category: Emerging Targets

Evidence Level: Level 2A

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.